MAP2K7 and Alzheimer disease: Moreover, knockdown of MEK increased autophagic lysosomal activity and decreased pTFEB level in the presence of Aβ42 oligomers (Supplementary Fig. 14), further supporting that trametinib’s suppression of MEK activity drove autophagic lysosomal activation in AD.